CoChat
Sign Up
Cited by 164Genetics and Neurodevelopmental DisordersGenomics and Rare DiseasesGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.

YY1 Haploinsufficiency Causes an Intellectual Disability Syndrome Featuring Transcriptional and Chromatin Dysfunction

Open access
Gabriele, Michele, Vulto-van Silfhout, Anneke T., Germain, Pierre-Luc, Vitriolo, Alessandro, Kumar, Raman, Douglas, Evelyn, Haan, Eric, Kosaki, Kenjiro, Takenouchi, Toshiki, Rauch, Anita, Steindl, Katharina, Frengen, Eirik, Misceo, Doriana, Pedurupillay, Christeen Ramane J., Stromme, Petter, Rosenfeld, Jill A., Shao, Yunru, Craigen, William J., Schaaf, Christian P., Rodriguez-Buritica, David, Farach, Laura, Friedman, Jennifer, Thulin, Perla, McLean, Scott D., Nugent, Kimberly M., Morton, Jenny, Nicholl, Jillian, Andrieux, Joris, Stray-Pedersen, Asbjørg, Chambon, Pascal, Patrier, Sophie, Lynch, Sally A., Kjaergaard, Susanne, Tørring, Pernille M., Brasch-Andersen, Charlotte, Ronan, Anne, van Haeringen, Arie, Anderson, Peter J., Powis, Zöe, Brunner, Han G., Pfundt, Rolph, Schuurs-Hoeijmakers, Janneke H.M., van Bon, Bregje W.M., Lelieveld, Stefan, Gilissen, Christian, Nillesen, Willy M., Vissers, Lisenka E.L.M., Gecz, Jozef, Koolen, David A., Testa, Giuseppe, de Vries, Bert B.A.·2017·The American Journal of Human Genetics
DOI 10.1016/j.ajhg.2017.05.006PMC PMC5473733
Open this paper in CoChat — free accountOpen PDF

Abstract

Yin and yang 1 (YY1) is a well-known zinc-finger transcription factor with crucial roles in normal development and malignancy. YY1 acts both as a repressor and as an activator of gene expression. We have identified 23 individuals with de novo mutations or deletions of YY1 and phenotypic features that define a syndrome of cognitive impairment, behavioral alterations, intrauterine growth restriction, feeding problems, and various congenital malformations. Our combined clinical and molecular data define "YY1 syndrome" as a haploinsufficiency syndrome. Through immunoprecipitation of YY1-bound chromatin from affected individuals' cells with antibodies recognizing both ends of the protein, we show that YY1 deletions and missense mutations lead to a global loss of YY1 binding with a preferential retention at high-occupancy sites. Finally, we uncover a widespread loss of H3K27 acetylation in particular on the YY1-bound enhancers, underscoring a crucial role for YY1 in enhancer regulation. Collectively, these results define a clinical syndrome caused by haploinsufficiency of YY1 through dysregulation of key transcriptional regulators.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajhg.2017.05.006

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Description of the Cohort (A) YY1 locus, including the location of the mutations identified in this study (top) and the (smoothed) frequency of non-pathogenic (missense) mutations in the ExAC Browser (in blue, bottom). (B) Frontal photographs sorted by age of individuals with YY1 mutations (a–j). Recurrent facial dysmorphism includes facial asymmetry, a broad forehead, fullness of the upper eyelids, and an upper lip shaped like a Gingko leaf. Each individual or his or her parents provided informed consent for the publication of these photographs. (C and D) YY1 levels in affected individuals’ LCLs as measured by western blot (C; the y axis indicates the ratio to β-tubulin, normalized on the first sample) and RNA-seq (D). In (D), each bar represents the mean across two samples for the probands and nine samples for the control individuals; error bars indicate standard deviation.
Figure 1 Description of the Cohort (A) YY1 locus, including the location of the mutations identified in this study (top) and the (smoothed) frequency of non-pathogenic (missense) mutations in the ExAC Browser (in blue, bottom). (B) Frontal photographs sorted by age of individuals with YY1 mutations (a–j). Recurrent facial dysmorphism includes facial asymmetry, a broad forehead, fullness of the upper eyelids, and an upper lip shaped like a Gingko leaf. Each individual or his or her parents provided informed consent for the publication of these photographs. (C and D) YY1 levels in affected individuals’ LCLs as measured by western blot (C; the y axis indicates the ratio to β-tubulin, normalized on the first sample) and RNA-seq (D). In (D), each bar represents the mean across two samples for the probands and nine samples for the control individuals; error bars indicate standard deviation.CC BY-NC-ND · PubMed Central
Figure 2 YY1 Variants on the 3D Structure of the Protein’s DNA Binding Domain The 3D structure of wild-type YY1’s C-terminal zinc-finger (ZN) domain is represented as a gray surface surrounding DNA, represented in gold. ZN coordination regions are reported in light green, and missense mutated amino acid residues are reported in violet. (A) Residues involved in polar interactions with D380 are reported in gray sticks. Hydrogen bonds are represented as yellow dashes. (B–D) Nucleotides interacting with residues L366 and F368 are reported in sticks. Distances between L366 (B), or its variants in individuals 2 (C) and 3 (D), and the closest nucleotides are reported with yellow dashes. (E) Putative structure of the truncated form of YY1 in proband 4 is reported through depiction of its electrostatic surface. (F) C-terminal portion of YY1 affected by proband 6 (variant in pink). The structure of the DNA-YY1 complex is reported from two opposite observation sides to highlight (1) its importance for ZN coordination in the fourth ZN and (2) its role in DNA binding. (G) Nucleotides interacting with K339 and R342 are reported in sticks. Polar interactions are reported with yellow dashes.
Figure 2 YY1 Variants on the 3D Structure of the Protein’s DNA Binding Domain The 3D structure of wild-type YY1’s C-terminal zinc-finger (ZN) domain is represented as a gray surface surrounding DNA, represented in gold. ZN coordination regions are reported in light green, and missense mutated amino acid residues are reported in violet. (A) Residues involved in polar interactions with D380 are reported in gray sticks. Hydrogen bonds are represented as yellow dashes. (B–D) Nucleotides interacting with residues L366 and F368 are reported in sticks. Distances between L366 (B), or its variants in individuals 2 (C) and 3 (D), and the closest nucleotides are reported with yellow dashes. (E) Putative structure of the truncated form of YY1 in proband 4 is reported through depiction of its electrostatic surface. (F) C-terminal portion of YY1 affected by proband 6 (variant in pink). The structure of the DNA-YY1 complex is reported from two opposite observation sides to highlight (1) its importance for ZN coordination in the fourth ZN and (2) its role in DNA binding. (G) Nucleotides interacting with K339 and R342 are reported in sticks. Polar interactions are reported with yellow dashes.CC BY-NC-ND · PubMed Central
Figure 3 ChIP-Seq for YY1 in LCLs Derived from Affected Individuals (A) Overlap between the peaks detected in each sample and each antibody. Each horizontal line represents a peak, shown in white if it was undetected in a sample, in light brown if it was detected in only one of the two IPs, and in dark brown if it was detected with both antibodies. Above are shown the sex of each LCL line, the YY1 mRNA expression and protein levels, and the coverage of the corresponding ChIP-seq experiments. TPM stands for transcripts per million, and FC stands for fold change in relation to the control samples. In red on the left are shown the average log-transformed read density and log enrichment for each peak. (B) Distribution of conserved and “lost” YY1 peaks across genomic features. (C) Dominant YY1 DNA-binding motif identified. (D) Top most-specific Gene Ontology (GO) enrichments of the YY1 target genes. (E) Principal-component analysis of the log-transformed enrichments over the input across the union of YY1-enriched regions. (F) YY1 enrichment over input across the different IPs (columns) and enriched regions (rows).
Figure 3 ChIP-Seq for YY1 in LCLs Derived from Affected Individuals (A) Overlap between the peaks detected in each sample and each antibody. Each horizontal line represents a peak, shown in white if it was undetected in a sample, in light brown if it was detected in only one of the two IPs, and in dark brown if it was detected with both antibodies. Above are shown the sex of each LCL line, the YY1 mRNA expression and protein levels, and the coverage of the corresponding ChIP-seq experiments. TPM stands for transcripts per million, and FC stands for fold change in relation to the control samples. In red on the left are shown the average log-transformed read density and log enrichment for each peak. (B) Distribution of conserved and “lost” YY1 peaks across genomic features. (C) Dominant YY1 DNA-binding motif identified. (D) Top most-specific Gene Ontology (GO) enrichments of the YY1 target genes. (E) Principal-component analysis of the log-transformed enrichments over the input across the union of YY1-enriched regions. (F) YY1 enrichment over input across the different IPs (columns) and enriched regions (rows).CC BY-NC-ND · PubMed Central
Figure 4 Transcriptional Impact of the YY1 Mutation (A) Principal-component analysis of the RNA-seq dataset. (B) Volcano plot of the differentially expressed genes (DEGs) highlights YY1-bound genes. (C) Expression of YY1-bound DEGs (left), along with the detected YY1 peaks at their TSS (right). (D) Top most-specific GO enrichments of the YY1-bound genes that show a significant association with YY1 mRNA levels across HapMap LCLs. (E) Overlap between the DEGs and YY1-bound and YY1-associated genes. (F) Top most-specific GO enrichments of all DEGs. (G) Expression of high-confidence DEGs (consistently dysregulated in the meta-analysis with the HapMap LCLs), along with eventual YY1 bindings at their TSS. In (C) and (G), expression is shown as Z scores of log-transformed normalized counts, and YY1 binding is indicated in light brown if it was detected in only one of the two IPs and in dark brown if it was detected with both antibodies.
Figure 4 Transcriptional Impact of the YY1 Mutation (A) Principal-component analysis of the RNA-seq dataset. (B) Volcano plot of the differentially expressed genes (DEGs) highlights YY1-bound genes. (C) Expression of YY1-bound DEGs (left), along with the detected YY1 peaks at their TSS (right). (D) Top most-specific GO enrichments of the YY1-bound genes that show a significant association with YY1 mRNA levels across HapMap LCLs. (E) Overlap between the DEGs and YY1-bound and YY1-associated genes. (F) Top most-specific GO enrichments of all DEGs. (G) Expression of high-confidence DEGs (consistently dysregulated in the meta-analysis with the HapMap LCLs), along with eventual YY1 bindings at their TSS. In (C) and (G), expression is shown as Z scores of log-transformed normalized counts, and YY1 binding is indicated in light brown if it was detected in only one of the two IPs and in dark brown if it was detected with both antibodies.CC BY-NC-ND · PubMed Central
Figure 5 YY1 Haploinsufficiency Results in Enhancer Dysregulation (A) Principal-component analysis of the H3K27ac read-count distribution across all enriched regions segregates proband from control samples (probands in red and controls in blue). (B) Distribution of H3K27ac read densities at YY1-bound enhancers shows a marked reduction in probands. RPKM stands for reads per kilobase pair per million reads mapped. (C) Preferential loss of H3K27ac at YY1-bound versus non-YY1-bound enhancers. The p value is the result of a two-tailed t-test. (D–F) Schematic representation of our key findings: YY1 haploinsufficiency and variants in the zinc-finger domain both result in a global loss of YY1 binding (D), associated with loss of H3K27ac (E); only a minority of differentially bound genes are differentially expressed, and the proportion is significantly higher for distal YY1 bindings (F).
Figure 5 YY1 Haploinsufficiency Results in Enhancer Dysregulation (A) Principal-component analysis of the H3K27ac read-count distribution across all enriched regions segregates proband from control samples (probands in red and controls in blue). (B) Distribution of H3K27ac read densities at YY1-bound enhancers shows a marked reduction in probands. RPKM stands for reads per kilobase pair per million reads mapped. (C) Preferential loss of H3K27ac at YY1-bound versus non-YY1-bound enhancers. The p value is the result of a two-tailed t-test. (D–F) Schematic representation of our key findings: YY1 haploinsufficiency and variants in the zinc-finger domain both result in a global loss of YY1 binding (D), associated with loss of H3K27ac (E); only a minority of differentially bound genes are differentially expressed, and the proportion is significantly higher for distal YY1 bindings (F).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 84 references

Cited by

Sorted by citations

Items 101–164 of 164

Related

See all

Metadata

Authors
Gabriele, M., Vulto-van Silfhout, A. T., Germain, P.-L., Vitriolo, A., Kumar, R., Douglas, E., Haan, E., Kosaki, K., Takenouchi, T., Rauch, A., Steindl, K., Frengen, E., Misceo, D., Pedurupillay, C. R. J., Stromme, P., Rosenfeld, J. A., Shao, Y., Craigen, W. J., Schaaf, C. P., Rodriguez-Buritica, D., Farach, L., Friedman, J., Thulin, P., McLean, S. D., Nugent, K. M., Morton, J., Nicholl, J., Andrieux, J., Stray-Pedersen, A., Chambon, P., Patrier, S., Lynch, S. A., Kjaergaard, S., Tørring, P. M., Brasch-Andersen, C., Ronan, A., van Haeringen, A., Anderson, P. J., Powis, Z., Brunner, H. G., Pfundt, R., Schuurs-Hoeijmakers, J. H. M., van Bon, B. W. M., Lelieveld, S., Gilissen, C., Nillesen, W. M., Vissers, L. E. L. M., Gecz, J., Koolen, D. A., Testa, G., & de Vries, B. B. A.
Affiliations
  • European Institute of Oncology (IT)
  • The University of Adelaide (AU)
  • South Australia Pathology (AU)
  • Keio University (JP)
  • University of Zurich (CH)
  • Oslo University Hospital (NO)
  • Baylor College of Medicine (US)
  • The University of Texas Health Science Center at Houston (US)
  • University of California San Diego (US)
  • University of Utah (US)
  • Children's Hospital of San Antonio (US)
  • Birmingham Women's Hospital (GB)
  • Hôpital Jeanne de Flandre (FR)
  • Centre Hospitalier Universitaire de Rouen (FR)
  • Children's Health Ireland at Crumlin (IE)
  • Odense University Hospital (DK)
  • Hunter Genetics (AU)
  • Women's and Children's Hospital (AU)
  • Ambry Genetics (United States) (US)
  • Radboud University Medical Center (NL)
  • University of Milan (IT)
Corresponding author
Testa, Giuseppe
ORCID
Venue
The American Journal of Human Genetics
Publisher
Elsevier BV
Published
2017-06
Volume
100
Issue
6
Pages
907-925
ISSN
0002-9297 (ISSN-L)
DOI
10.1016/j.ajhg.2017.05.006
PMC
PMC5473733
OpenAlex
W2620797288
Cited by
163
References
84
Citations by year
2026: 14 · 2025: 16 · 2024: 18 · 2023: 15 · 2022: 17 · 2021: 28 · 2020: 17 · 2019: 21 · 2018: 11 · 2017: 4
FWCI
9.60
Type
journal article
Language
en
Open access
Licence
Locations
  • The American Journal of Human Genetics (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
  • Leiden Repository (Leiden University) (submittedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-nd)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
  • Radboud Repository (Radboud University) (submittedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc-nd)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • European Commission (241995)
  • European Research Council (DISEASEAVATARS 616441)
  • Telethon Foundation (GGP13231B, GGP14265)
  • Associazione Italiana per la Ricerca sul Cancro
  • Regione Lombardia (Ricerca Indipendente 2012)
  • Umberto Veronesi Foundation
  • Italian Ministry of Health (ERANET-Neuron grant, Ricerca Corrente grant)
  • Japan Agency for Medical Research and Development
  • Australian National Health and Medical Research Council (1091593)
  • Dutch Organization for Health Research and Development (917-86-319, 912-12-109)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
YY1, haploinsufficiency, intellectual disability, de novo mutations, zinc finger transcription factor, chromatin binding, enhancer regulation, H3K27 acetylation, transcriptional dysregulation, fetal growth restriction, congenital malformations, behavioral alterations
MeSH terms
Protein Domains, Acetylation, Adolescent, Base Sequence, Child, Preschool, Chromatin, Enhancer Elements, Genetic, Female, Haplotypes, Histones, Humans, Lymphocytes, Male, Intellectual Disability, Methylation, Models, Molecular, Protein Binding, Transcription, Genetic, Cohort Studies, Mutation, Missense, Chromatin Immunoprecipitation, YY1 Transcription Factor, Haploinsufficiency, Hemizygote, Gene Ontology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review